Data show clinical benefit from mitral valve clip device

Sep 21, 2010

A percutaneous mitral valve clip designed to stop mitral valve regurgitation demonstrated clinical benefit as measured by the degree of mitral regurgitation, according to a study presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. Mitral valve regurgitation is one of the most common forms of heart disease.

The study was led by James Hermiller, MD, Director of Cardiovascular Intervention at the St. Vincent Heart Center of Indiana (Indianapolis, IN.)

"Significant measures of clinical benefit are observed one year following successful therapy," said Dr. Hermiller.

The study, EVEREST II, is a prospective, multi-center, randomized designed to compare the safety and effectiveness of the MitraClip System with in the treatment of mitral regurgitation (MR). Measures of 12-month clinical benefit, defined as improvements in left ventricular (LV) function and symptomatic improvement, were evaluated for the Device Group and Control Group, and have been previously reported. However, observed clinical benefit by 12 month MR grade has not been reported.

Significant improvement in LV function, NYHA Functional Class, and Quality of Life scores was observed for all device patients with ongoing success (MR≤2+ at 12 months). Patients with MR reduced to 1+, 1+ to 2+, or 2+ at 12 months demonstrated marked clinical benefit, with significant improvements noted from baseline to 12 months.

A detailed analysis of these data will be presented during The 'Best of the Best' TCT 2010 Abstracts Session on Friday, September 24 in the Main Arena at the Washington Convention Center.

Explore further: New drug sales help boost Novartis Q1 profit (Update)

Provided by Cardiovascular Research Foundation

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Open chest surgery alternative found

Nov 20, 2006

A U.S. scientist has found an alternative to open chest surgery in treating mitral regurgitation -- blood leaking into the heart through the mitral valve.

Mount Sinai performs first tricuspid ring implantation

Sep 13, 2010

David H. Adams, MD, Marie-Josée and Henry R. Kravis Professor and Chairman of the Department of Cardiothoracic Surgery at The Mount Sinai Medical Center, has performed the first implantation of the Medtronic Tri-Ad ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Google+ boss leaving the company

The executive credited with bringing the Google+ social network to life is leaving the Internet colossus after playing a key role there for nearly eight years.